Novel Mitochondria-Targeting Peptide in Heart Failure Treatment: A Randomized, Placebo-Controlled Trial of Elamipretide
MA Daubert, E Yow, G Dunn, S Marchev… - Circulation: Heart …, 2017 - Am Heart Assoc
Background Mitochondrial dysfunction and energy depletion in the failing heart are
innovative therapeutic targets in heart failure management. Elamipretide is a novel
tetrapeptide that increases mitochondrial energy; however, its safety, tolerability, and
innovative therapeutic targets in heart failure management. Elamipretide is a novel
tetrapeptide that increases mitochondrial energy; however, its safety, tolerability, and
For custom peptides, please visit www.pepmic.com. Our peptide services including but not limited to:
*Peptide Synthesis: From short peptides to long peptides, linear peptides to cyclic peptides.
*Peptide Modifications: Peptide-protein conjugation, D-amino acid peptides, isotope peptides, fluorescent peptides, multiple antigen peptides, multiple disulfide bridge peptides, phosphopeptides etc.
*Catalog Peptides: ACE Inhibitors, Amyloids & Related Peptides, Antimicrobial Peptides, Apelin Peptides, Myelin Oligodendrocyte Glycoprotein (MOG) Peptides, TAT Proteins etc.
*Peptide Salt: TFA, Desalt, Acetate, HCl.
*Peptide Purity: From crude to ＞99.5%.
*Production Capacity: From mg to kg, with a capacity of synthesizing 15,000 peptides/month.
*Peptide Library Synthesis: Alanine Scan, Overlapping, Positional Scan, T-cell Truncated, Scrambled ect.
Quick Links:
Contact Information:
Eva He
eva@pepmic.com
Pepmic Co., Ltdeva@pepmic.com
www.pepmic.com
没有评论:
发表评论